Table 2. Clinicopathological characteristics, treatment, and outcomes of patients with recurrence of uterine serous carcinoma.

Case	Age	Stage	Depth of invasion	Cervical stromal involvement	LVSI	Pelvic cytology	Tumor size (mm)	Site of recurrence	Treatment for recurrence	DFS (mo)	Status at last follow-up
1	62	IA	<50%	Present	Present	Positive	38	Peritoneum+PLN	Chemotherapy	11	DOD
2	61	II	<50%	Absent	Absent	Positive	55	Peritoneum	Chemotherapy	15	DOD
3	65	II	≥50%	Absent	Absent	Negative	25	Peritoneum	Chemotherapy	19	DOD
4	72	II	≥50%	Absent	Absent	Positive	33	Peritoneum	Chemotherapy	5	DOD
5	72	IA	Endometrium	Present	Absent	Positive	25	Peritoneum	Chemotherapy	10	LOF
6	76	IA	Endometrium	Present	Absent	Negative	25	Lung+pericardium+cervical lymph node	Chemotherapy	36	DOD
7	58	IA	<50%	Present	Absent	Positive	37	Lung, abdominal mass	Chemotherapy	5	DOD
8	77	II	≥50%	Absent	Present	Negative	42	Lung	Chemotherapy	22	DOD
9	66	II	<50%	Absent	Absent	Negative	25	Brain+lung	RT	67	DOD
10	64	IA	<50%	Present	Absent	Negative	29	Vagina (12 mo), lung (27 mo)	IVRT+surgery	12	NED
11	78	II	≥50%	Absent	Present	Negative	90	Vagina	IVRT	4	DOD
12	77	II	≥50%	Absent	Present	Negative	60	Vagina	IVRT	7	DOD
13	73	IA	Endometrium	Present	Absent	Positive	20	Liver+pelvic mass	Chemotherapy	41	DOD
14	58	IB	≥50%	Present	Present	Positive	40	Pleura	Chemotherapy	26	DOD
15	63	IA	<50%	Present	Present	Positive	15	Mesentery	Surgery+RT	21	NED
16	61	IB	≥50%	Present	Present	Negative	35	PAN+Virchow's node+subcutaneous tumor	Chemotherapy+RT	17	DOD
17	62	IA	<50%	Present	Absent	Negative	25	PAN	Surgery+RT	10	NED
18	67	II	<50%	Absent	Absent	Negative	100	PAN	Chemotherapy	8	NED

DFS, disease-free survival; DOD, death on disease; IVRT, intravaginal radiotherapy; LOF, loss of follow-up; LVSI, lymphovascular space invasion; NED, no evidence of disease; PAN, para-aortic lymph node; PLN, pelvic lymph node; RT, radiation therapy.